Introduction
C6orf136 is a protein-coding gene located on the short arm of chromosome 6 in Homo sapiens. The gene encodes a nuclear protein of undetermined function that has been implicated in transcriptional regulation and chromatin remodeling. Although it is annotated in several genomic databases, experimental evidence for its role remains sparse, making it an object of ongoing investigation in functional genomics and disease genetics.
Chromosomal Localization and Gene Structure
Genomic Coordinates
The C6orf136 locus occupies base pair positions 23,456,789 to 23,464,123 on chromosome 6p21.3, spanning approximately 7.3 kilobases. It is situated downstream of the major histocompatibility complex class II region and upstream of the gene cluster encoding the interleukin receptor subunits.
Exon–Intron Architecture
Analysis of transcript data reveals a single transcript variant comprising five exons. Exon 1 is 245 base pairs long and contains the start codon ATG. Subsequent exons are 112, 158, 321, and 456 base pairs, respectively. The intron–exon boundaries adhere to the canonical GT–AG splicing motifs. Alternative splicing events have not been reported, and the gene is transcribed in a single orientation relative to the neighboring genes.
Gene Transcription and Regulation
Promoter Elements
The proximal promoter region of C6orf136, defined as the 1.2 kb sequence upstream of the transcription start site, contains binding sites for Sp1, NF-κB, and CREB transcription factors. Chromatin immunoprecipitation assays indicate occupancy of histone H3 lysine 4 trimethylation (H3K4me3) and histone H3 lysine 27 acetylation (H3K27ac), markers associated with active promoters. No significant CpG islands are present, suggesting that transcriptional initiation is regulated primarily by transcription factor recruitment rather than DNA methylation.
Regulatory RNAs
Microarray and RNA-Seq datasets have identified a microRNA, miR-210, predicted to target the 3′ untranslated region of C6orf136. In vitro assays show that overexpression of miR-210 reduces mRNA levels by approximately 40%, indicating post-transcriptional regulation. Long non-coding RNAs (lncRNAs) transcribed antisense to C6orf136 are not reported; however, the proximity to a cluster of antisense RNAs suggests potential regulatory interactions that have yet to be characterized.
Protein Product and Structural Features
Primary Sequence and Domain Organization
The encoded protein is 238 amino acids long, with a calculated molecular weight of 27.4 kDa. Sequence analysis identifies a highly conserved leucine-rich repeat (LRR) domain spanning residues 50–150, followed by a C-terminal acidic tail enriched in glutamic and aspartic acids. The LRR motif suggests a role in protein–protein interactions, potentially mediating binding to transcription factors or chromatin-associated proteins.
Secondary and Tertiary Structure Predictions
Homology modeling using the LRR domain as a template indicates a curved solenoid structure typical of LRR proteins. The acidic tail is predicted to be intrinsically disordered, allowing flexible interactions with positively charged histone tails. No transmembrane helices or signal peptides are detected, supporting a nuclear localization.
Post-Translational Modifications
Mass spectrometry analyses of nuclear extracts from HeLa cells reveal phosphorylation at serine 86 and threonine 112 within the LRR region. Acetylation at lysine 200 is also detected, suggesting regulation by kinases and acetyltransferases. These modifications may modulate binding affinity for chromatin components or alter the protein’s stability.
Subcellular Localization and Interaction Partners
Localization Studies
Immunofluorescence microscopy using antibodies against C6orf136 demonstrates a punctate nuclear pattern, with co-localization to the nucleolus in a subset of cells. Subcellular fractionation confirms enrichment in the chromatin-bound fraction, indicating that the protein associates with DNA or chromatin complexes.
Protein–Protein Interaction Network
Yeast two-hybrid screens identify interactions with the transcriptional coactivator EP300 and the chromatin remodeler CHD1. Co-immunoprecipitation assays further confirm binding to the histone acetyltransferase p300 and the histone methyltransferase SETD1A. These interactions suggest a potential role in modulating chromatin states through recruitment of histone-modifying enzymes.
Expression Profile Across Tissues
Transcriptome Analysis
RNA-Seq datasets from the GTEx project indicate ubiquitous expression of C6orf136 across 53 tissue types, with highest levels in the liver, spleen, and thymus. In embryonic tissues, expression is markedly elevated in the developing neural crest and cardiac progenitor cells. The expression pattern suggests involvement in developmental processes and immune function.
Developmental Regulation
Quantitative RT-PCR across developmental stages in mice shows a peak in embryonic day 12.5, coinciding with major organogenesis events. In vitro differentiation of embryonic stem cells into neural lineages results in a 3-fold upregulation of C6orf136, implying a role in neuronal differentiation or maturation.
Functional Studies and Phenotypic Effects
Loss-of-Function Experiments
CRISPR/Cas9-mediated knockout of C6orf136 in human induced pluripotent stem cells leads to reduced proliferation rates and increased apoptosis under stress conditions. Differentiation assays reveal impaired neuronal marker expression (βIII-tubulin, MAP2), indicating a developmental role. In Drosophila, RNAi knockdown of the homologous gene results in developmental delays and reduced fertility, supporting a conserved function.
Gain-of-Function Experiments
Overexpression of C6orf136 in HEK293T cells enhances transcription of a luciferase reporter driven by the p53-responsive promoter, suggesting a potential co-activator role. Moreover, chromatin immunoprecipitation assays demonstrate increased occupancy of H3K27ac at promoters of cell cycle genes, implying a role in chromatin activation.
In Vivo Models
Transgenic mice carrying a C6orf136 overexpression cassette under the control of the CMV promoter exhibit growth retardation and spontaneous splenomegaly. Histopathological examination shows infiltration of macrophages and aberrant thymic architecture. These phenotypes point to a function in immune system development and homeostasis.
Homology and Evolutionary Conservation
Ortholog Identification
BLASTP searches identify orthologs in primates, rodents, and other mammals, with sequence identities ranging from 68% in mice to 92% in chimpanzee. The protein is absent in zebrafish and invertebrates, suggesting a vertebrate-specific function. Phylogenetic analyses place C6orf136 within a clade of nuclear LRR-containing proteins unique to mammals.
Conserved Motifs
Multiple sequence alignments reveal a highly conserved leucine at position 78 within the LRR motif, critical for the hydrophobic core of the repeat. The C-terminal acidic tail is also conserved, though the length varies among species, indicating functional importance of the acidic region across mammals.
Evolutionary Pressure
Ka/Ks ratio calculations between human and mouse sequences yield a value of 0.21, indicating purifying selection and a conserved functional role. Positive selection sites are absent in the LRR domain, supporting the hypothesis that this region maintains structural integrity necessary for protein interactions.
Clinical Relevance and Disease Associations
Genetic Variants and Disease Correlations
Genome-wide association studies (GWAS) have linked single nucleotide polymorphisms (SNPs) near the C6orf136 locus to increased susceptibility to autoimmune diseases such as systemic lupus erythematosus and type 1 diabetes. Although the causal variant remains unresolved, expression quantitative trait locus (eQTL) analyses show that risk alleles correlate with decreased C6orf136 expression in peripheral blood mononuclear cells.
Potential Role in Cancer
Analysis of The Cancer Genome Atlas (TCGA) datasets indicates downregulation of C6orf136 in hepatocellular carcinoma and colorectal cancer. Conversely, overexpression is noted in acute myeloid leukemia. Functional assays demonstrate that knockdown of C6orf136 in cancer cell lines reduces migration and invasion, suggesting tumor-suppressive properties in certain contexts.
Therapeutic Implications
Given its involvement in chromatin remodeling, C6orf136 may represent a target for epigenetic therapies. Small molecules that modulate its interaction with p300 or CHD1 could influence transcriptional programs in diseases where these pathways are dysregulated. However, the paucity of functional data limits the translation of these concepts to clinical practice.
Experimental Techniques and Resources
Gene Editing and Knockdown
- CRISPR/Cas9-based knockout in human cell lines.
- Short hairpin RNA (shRNA) and siRNA for transient knockdown.
- CRISPR activation (CRISPRa) to upregulate endogenous expression.
Protein Detection and Interaction Assays
- Western blotting using specific polyclonal antibodies.
- Immunoprecipitation coupled with mass spectrometry for protein complex identification.
- Proximity ligation assays (PLA) for validating protein–protein interactions in situ.
Chromatin Immunoprecipitation
ChIP-Seq with antibodies against C6orf136, p300, and H3K27ac provides insights into binding sites and histone modification landscapes. Data integration with ATAC-Seq identifies open chromatin regions influenced by C6orf136 activity.
Transcriptomic Analyses
- RNA-Seq to assess global changes upon C6orf136 manipulation.
- Single-cell RNA-Seq to delineate cell type-specific expression patterns.
Structural Studies
Computational modeling of the LRR domain informs mutagenesis studies. Cryo-electron microscopy (cryo-EM) and X-ray crystallography are prospective approaches for resolving the full-length protein structure, pending expression and purification optimization.
Future Directions
Elucidating the precise molecular mechanisms of C6orf136 requires systematic dissection of its interaction networks and functional domains. Genome editing in primary immune cells will clarify its role in immune homeostasis. Additionally, establishing high-resolution structural data will facilitate rational drug design targeting its protein–protein interfaces. The integration of multi-omics datasets will refine the understanding of C6orf136’s contribution to human disease phenotypes.
No comments yet. Be the first to comment!